Loading clinical trials...

Triage Survey for Psychiatry Research Eligibility | Clinical Trials | Clareo Health

UNKNOWN

Triage Survey for Psychiatry Research Eligibility

NCT05800925•Adams Clinical

Summary

TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed.
•Participant is at least 18 years old.

Exclusion Criteria

•Participant is pregnant, breast-feeding, or planning to become pregnant.
•History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results.
•Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on C-SSRS questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening.
•Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant.
•Any condition that in the investigator's opinion makes a participant unsuitable for the study.
•Currently employed by Adams Clinical or a first-degree relative of an employee.

Locations (3)

Copley Clinical

Boston, Massachusetts, United States

Adams Clinical

Watertown, Massachusetts, United States

Berman Clinical

New York, New York, United States

Key Dates

Start Date

December 21, 2021

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

October 23, 2023

Enrollment

2,000

ESTIMATED participants

Conditions

Major Depressive DisorderBorderline Personality DisorderGeneralized Anxiety Disorder

Interventions

Survey

OTHER

Contacts

Miriam Evans, PhD

CONTACT

617-744-8542 mevans@adamsclinical.com

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 23, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Triage Survey for Psychiatry Research Eligibility

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)